Rapamycin: The Complete Guide

Rapamycin was isolated from soil bacteria on Easter Island (Rapa Nui) and named for that origin. It inhibits mTOR (mechanistic target of rapamycin), a nutrient-sensing pathway that pushes growth when food is abundant and eases off during scarcity.

In transplant medicine, daily rapamycin helps prevent organ rejection by dialing down immune cell proliferation. The longevity hypothesis is different: intermittent, lower-intensity mTOR inhibition might mimic some benefits of caloric restriction — better autophagy, less unneeded growth signaling — without living in a chronic fast.

That hypothesis is why Attia, academic geroscience labs, and cash-pay longevity clinics talk about it constantly. It is also why this guide will not give a home protocol. Off-label use belongs inside a doctor-patient relationship with bloodwork.

Mice: the National Institute on Aging Interventions Testing Program found rapamycin extended lifespan in genetically heterogeneous mice, including when treatment started later in life. That reproducibility across sites is why researchers treat it as the benchmark geroprotective drug in rodents.

Mechanistically, mTORC1 inhibition can increase autophagy and change immune-cell aging. The details are messy: too much inhibition for too long looks like immunosuppression; the 'pulse' idea tries to keep the autophagy signal without living in transplant-level immune suppression.

Humans: we have decades of safety familiarity from transplant (a different dose and context). Aging-specific human data include immune-response studies (e.g., Mannick and colleagues on mTOR inhibition and vaccine response in older adults) and small trials on skin and other proxies. Large, long outcome trials for healthy-aging lifespan do not exist yet.

What responsible clinics do: confirm there is a reason to consider off-label therapy, review drug interactions, run baseline labs (CBC, metabolic panel, lipids, HbA1c, sometimes hs-CRP), and follow mouth sores, infections, and wound-healing issues. Dosing schedules used in research and clinics differ from daily transplant regimens — your prescriber chooses, not a forum spreadsheet.

What they also do: keep the boring longevity stack in place. Rapamycin is not a substitute for Zone 2, strength training, sleep, or not smoking. Several clinicians will not discuss it until those are in motion.

What they do not do, and you should not either: buy 'research chemical' sirolimus, split veterinary tablets from unregulated sellers, or copy someone else's milligram schedule from Reddit or X.

Many users report nothing obvious in the first weeks. Some notice mouth ulcers (aphthous sores), which are a classic mTOR-inhibitor signal that the dose or frequency may be too aggressive.

Subjective energy or 'recovery' stories are mixed and highly placebo-prone. Take them as anecdotes. Track infections, lipids, and how wounds heal instead.

Documented concerns: increased infection risk, stomatitis, delayed wound healing, elevations in triglycerides/LDL, edema, and rare but serious transplant-dose toxicities (including impaired kidney function and lung issues) that your clinician screens for.

It can interact with other drugs metabolized by CYP3A4. Grapefruit, certain antifungals, and a long list of prescriptions matter here.

Cost varies wildly by pharmacy, insurance, and whether you are on a labeled indication. Longevity-clinic programs add visit and lab fees. If a website offers 'research rapamycin' without a prescription, treat that as a hard stop.

r/longevity treats rapamycin as the most serious pharmaceutical conversation in the space — more so than NMN — because of the ITP data. The split is 'wait for better human trials' versus 'I'm already at a clinic with labs.'

Attia has discussed his own physician-supervised use publicly while emphasizing uncertainty. That combination — curiosity plus humility — is the correct posture. Sinclair-era NAD marketing is not the model here.